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Abstract The successful ex vivo reconstruction of human bone marrow is an extraordinarily important basic 
scientific and clinical goal. Fundamentally, the system is the paradigm of a complex interactive tissue, in which the 
proliferation and regulated differentiation of one parenchymal cell type (the hematopoietic stem cell) is governed by the 
surrounding stromal cells. Understanding and reproducing the molecular interactions between bone marrow stromal 
cells and stem cells in tissue culture models is  therefore the critical step in successful bone marrow tissue culture. 
Clinically, successful reconstruction of human bone marrow would permit the controlled production of mature blood 
cells for transfusion therapy, and immature bone marrow stem cells for bone marrow transplantation. In approaching 
the bone marrow culture system, we recognize the critical role that hematopoietic growth factors (HGFs) play in 
hematopoiesis. Since stromal cells in traditional human bone marrow cultures produce little HGFs, we have begun by 
asking whether local supplementation of hematopoietic growth factors via genetically engineered stromal cells might 
augment hematopoiesis in liquid cultures. The results indicate that locally produced GM-CSF and IL-3 do augment 
hematopoiesis for several weeks in culture. In combination with geometric and dynamic approaches to reconstructing 
physiological bone marrow microenvironments, we believe that this approach has promise for reconstructing human 
bone marrow ex vivo, thereby permitting i ts application to a variety of basic and clinical problems. 
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If one could successfully recreate the physiol- 
ogy of human bone marrow ex vivo, one could 
achieve several aims: 1) the detailed analysis of 
normal and leukemic hematopoiesis; 2) the ma- 
nipulation of human bone marrow stem cells, 
including stem cell expansion for bone marrow 
transplantation, tumor cell purging of contami- 
nated bone marrow prior to autologous trans- 
plantation, and (e.g., retroviral mediated) gene 
transfer into stem cells; and 3) the controlled 
production of mature blood cells for transfusion 
therapy. 
These and other potential applications of long- 
term bone marrow culture have been evident 
since the original experiments of Dexter and 
Lajtha [l l ,  which demonstrated that murine 
liquid bone marrow cultures could continue to 
produce progenitor cells and mature myeloid 
cells for over one year. However, attempts to 
extend these principles to human liquid marrow 
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culture, and to improve the efficiency of such 
cultures, have been notably unsuccessful. Hu- 
man liquid bone marrow cultures produce con- 
tinually decreasing numbers of mature blood 
cells and progenitors, and generally dissipate 
completely by 8-10 weeks [2 ,3] .  Moreover, cell 
production appears to be quite skewed towards 
myeloid cell production, particularly monocytes, 
and erythroid hematopoiesis is notably absent, 
even when erythropoietin is added. In fact, there 
is little reason to think that human liquid bone 
marrow cultures, as they are currently per- 
formed, promote stem cell survival and expan- 
sion to any significant extent. Thus the ineffi- 
ciency of current human liquid bone marrow 
culture techniques has prevented its exploita- 
tion for the analysis and manipulation of human 
stem cells in vitro, and failed to permit the 
generation of mature blood cells in sufficient 
numbers to consider scale-up for clinical transfu- 
sion therapy. 
We believe that recent advances in our under- 
standing of hematopoietic cell and molecular 
biology, as well as in the cellular bioengineering 
of complex cultures, now permit us to rationally 
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approach developing a truly efficient ex vivo 
model of human bone marrow. We have identi- 
fied five distinct, but potentially interrelated 
areas in which current liquid marrow cultures 
fail to reproduce in vivo bone marrow design: 1) 
failure of quiescent cultured stromal cells to 
secrete hematopoietic growth factors; 2) lack of 
a normal, compact 3-dimensional geometry with 
stromal cells and extracellular matrix proteins 
at high density; 3) accumulation of toxic metab- 
olites in traditional batch marrow cultures, 
which may poison stromal cells, hematopoietic 
cells, or both; 4) degradation of the cultured 
stromal and early hematopoietic cells by the 
toxic granular contents of mature granulocytes 
and macrophages that accumulate in liquid cul- 
tures; and 5) depletion of stem cells resulting 
from frequent sampling of non-adherent cells by 
the investigator. We hypothesize that the pre- 
cise analysis and solution of these problems will 
lead to greatly improved human bone marrow 
cultures, which will permit improved analysis 
and manipulation of human bone marrow cul- 
tures for bone marrow transplantation and ma- 
ture blood cell transfusion. 
STROMAL CELL PRODUCTION OF 
HEMATOPOIETIC GROWTH FACTORS 
The hematopoietic microenvironment, or 
stroma, has long been known to be a major 
architectural feature of bone marrow, including 
a complex meshwork of cells and extracellular 
matrix. Although the precise roles of these cells 
and matrix components was not early realized 
[41, it was immediately clear that without such a 
stroma hematopoiesis would rapidly die out. If 
no attempt was made to remove these stromal 
elements, hematopoiesis was maintained for pe- 
riods of weeks to months [5]. This requirement 
for stromal accessory cells has been documented 
by many laboratories [6-81, and recently we and 
others have isolated homogeneous fibroblastoid 
cell strains that appear to perform as well as 
more complex stromal cell mixtures [9,101. 
The stromal cells and matrix proteins appear 
to provide two sorts of requisites for hematopoie- 
sis: 1) secreted hematopoietic growth factors, or 
colony stimulating factors (CSFs) and 2) an 
adhesive microenvironment that maintains both 
high local growth factor concentrations and cell- 
cell contact. To date, stromal fibroblasts and 
endothelial cells have been shown to be capable 
of producing granulocyte-macrophage colony 
stimulating factor (GM-CSF), granulocyte col- 
ony stimulating factor (G-CSF), interleukin 6 
(IL-6), and probably macrophage colony stimu- 
lating factor (M-CSF) 111-171. These polypep- 
tides clearly support progenitor cell prolifera- 
tion and differentiation, and may contribute to 
stem cell survival and proliferation as well. Sev- 
eral other hematopoietic growth factors have 
been described which are products of T lympho- 
cytes or monocytes, including interleukms 1, 3, 
4 and 5 [18-21]. Of these, IL-3 and GM-CSF are 
particularly interesting, because murine stem 
division sufficient to permit incorporation of 
transfected genetic material was promoted by 
WEHI-3 supernatants containing IL-3 and GM- 
CSF [22]. 
The true in vivo stimuli for the production of 
these HGFs is not known. In vitro, however, 
endothelial cells and fibroblasts from a variety 
of tissues can transcribe and secrete GM-CSF, 
G-CSF, and IL-6 in response to signals provided 
by activated macrophages, such as 1L-1 and 
tumor necrosis factor [ll-171. T cells and acti- 
vated monocytes are therefore required for the 
in vitro production of all of these CSFs. This 
requirement may explain, in large part, why 
human liquid bone marrow cultures “run down” 
after a few weeks. Without exogenous stimuli, 
human T cells die in liquid culture, while mono- 
cytes remain quiescent. Thus, once the T cells 
die out and monocytes are no longer activated, 
the fibroblasts and endothelial cells may no 
longer secrete CSFs and the bone marrow stem 
cells die. A continuous source of the proper 
CSFs, on the other hand, might circumvent this 
problem. 
TOXIC PRODUCTS FROM MATURE CELLS 
ROLE OF MEDIUM EXCHANGE 
AND METABOLIC WASTE PRODUCTS-THE 
A critical observation from the liquid culture 
experience is that secreted products of mature 
granulocytes and macrophages are toxic to the 
immature developing marrow cells. Initially, we 
observed that removal of maturing myeloid cells 
permitted the otherwise unobserved growth of 
erythroid and megakaryocytic cells in vitro [91. 
We also found that such cultures generated more 
cells and grew longer than traditional whole 
marrow cultures. Re-adding mature myeloid cells 
to the original marrow innoculum returned the 
system to a low efficiency state. More recently, 
macrophages arising in liquid cultures have been 
shown to directly damage cultured stroma and 
immature hematopoietic cells [23]. These re- 
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sults suggest that the slow but continuous perfu- 
sion of culture medium, removing mature cells 
as they lose their stromal adhesion receptors, 
would protect the culture microenvironment 
from the toxic granular and other secreted prod- 
ucts of the mature myeloid cells. 
Attempts to duplicate in vivo bone marrow 
perfusion conditions can now be built on the 
growing theoretical and practical experimental 
advances achieved with perfusion culture tech- 
nologies from other systems. These advances 
have been made, in part, by the recognition of 
the differences between static in vivo culture 
systems and the dynamic in vivo situation. Per- 
haps the most important is the delivery of oxy- 
gen and nutrients, and the removal of inhibitory 
end products, such as lactate and ammonium 
ions [24]. For example glutamine has received 
particular attention as a major energy source 
for culture cells. As a consequence glutamine 
concentrations are often rapidly reduced to 
critically low values in static culture medium. 
Conversely, lowering peak concentrations of glu- 
tamine and glucose through continuous perfu- 
sion with lower glutamine and glucose concentra- 
tions can reduce the build-up of inhibitory end 
products, such as lactic acid and ammonium 
1251. 
Local oxygen concentrations are another criti- 
cal variable that is poorly modeled by static in 
vivo cultures. The solubility of oxygen in aque- 
ous medium is low and concentrations surround- 
ing a cell line growing on a flat surface only 1 
mm beneath the surface of the medium have 
been estimated to be only 60% of that at  the 
surface. The balance between the rate of oxygen 
consumption and rate of supply by diffusion 
that exists in vivo is thus disrupted. Several 
methods of enhancing 0, delivery in bioreactors 
have been developed, including gentle rocking 
with intermittent exposure to air [261, stirred 
tank reactors [27,28], surface aeration [291, mi- 
crocarrier cultures [ 301 and airlift fermenters 
[31-353. As discussed below, our perfusion cham- 
bers compare very favorably with these methods 
without introducing excessive shear stresses. 
Overall, we believe that the careful application 
of continuous perfusion technology to he- 
matopoietic cultures can solve the problems of 
mature cell toxic secreted products, metabolite 
delivery and removal, and oxygenation which 
are inherent and severe in tradition T-flask Dex- 
ter cultures. 
IS STEM CELL SURVIVAL A SOLVABLE 
PROBLEM? 
Since the central goal of this project is the 
long-term maintenance of human bone marrow 
stem cells in vivo, it is critical to ask: Can this be 
done? What makes one think that this is a 
reasonable hope? Several lines of argument are, 





Long-term static liquid culture systems in 
the mouse have been maintained for 1 year 
or more [1,32,331. Since the physiologies of 
murine and human hematopoiesis appear 
to be analagous (homologous hematopoie- 
tic growth factors, produced by similar stro- 
ma1 and circulating cells), this suggests 
that the failure to construct at least stable, 
low efficiency long-term human stem cell 
cultures is a technical and quantitative, 
not qualitative, failure. 
Studies on human patients with chronic 
myelogenous leukemia indicate that stem 
cells placed into liquid culture probably do 
not die immediately. Instead, normal stem 
cells, whose progenitor progeny are not 
evident in the initial culture, persist and 
divide over the next two months, giving 
rise to clonable progenitor cells [34]. Since 
the transit time from stem cell to progeni- 
tor is unlikely to be long, this suggests that 
the initially plated stem cells are capable of 
surviving for a month or more, even in 
traditional, inefficient cultures. 
Recent experiments using retroviral trans- 
fection to randomly incorporate marker 
genes followed by bone marrow transplan- 
tation indicate that an entire hematopoie- 
tic system may be repopulated from less 
than 5 stem cells, perhaps a single cell [22]. 
Thus, if advances made in culture prac- 
tices succeeded in keeping only a fraction 
of the total stem cell pool alive, one should 
still be able to engineer a stable, efficient 
bone marrow ex vivo. 
Stem cells survive and proliferate in vivo. 
Bone marrow transplants are routinely per- 
formed using donors > 40 years old, with 
no evidence for a higher engrafting dose 
required than for childhood donors. There 
is no evidence that even a significant frac- 
tion of the stem cell pool is lost over de- 
cades in vivo. Therefore, in principle, stem 
cells should be supportable if the in vivo 
environment can be accurately mimicked. 
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Fig. 1. Nonadherent progenitor cells arising in liquid culture from lo7 bone marrow mononu- 
clear cells plated over normal marrow adherent layers (closed circles), GM-CSF transfected 
NIH-3T3 cells (open circles), and GM-CSF/IL-3 transfected NIH-3T3 cells (closed squares). 
Untransfected NIH-3T3 cells failed to support any progenitor cell production for longer than 2 weeks. 
Overall, these are persuasive arguments that 
it should be possible to keep human stem cells 
alive in vivo, under the proper circumstances. 
With the recent advances in hematopoietic cell 
biology, molecular genetics, and cellular bioengi- 
neering, we believe that now is the time to 
productively tackle and solve this problem. 
GROWTH FACTOR SUPPLEMENTATION WITH 
TRANSFECTED STROMAL CELLS 
We have therefore begun to address each of 
these problems with traditional human liquid 
bone marrow cultures, with the goal of develop- 
ing and building a high efficiency ex vivo bone 
marrow. Our fundamental approach has been to 
begin by understanding the ways in which tradi- 
tional cultures differ from hematopoiesis in vivo, 
and to adapt our culture systems to either better 
reflect the in vivo physiology or to bypass those 
physiologic requirements observed in vivo. As 
one example of this approach, we have used 
recombinant DNA technology to bypass the re- 
quirement for inflammatory induction of CSF 
production by bone marrow stromal cells. While 
bone marrow stromal cells in vivo undoubtedly 
secrete CSFs in the basal state, once explanted 
they fail to secrete CSFs unless stimulated with 
IL-la or TNFa. To circumvent this limitation, 
while providing for the local secretion and pre- 
sentation of CSFs as normally occurs in the 
bone marrow, we have therefore created NIH- 
3T3 fibroblast cell lines transfected with plas- 
mid constructs containing both a full length 
GM-CSF and IL-3 cDNAs driven by the metal- 
lothionine promoter and SV40 enhancer, which 
secrete these CSFs at 0.2-0.5 ng/106 cells/day 
[351. Utilizing these transfected fibroblast cell 
lines, we have established liquid marrow cul- 
tures under both traditional Dexter medium 
exchange schedules and more rapid, physiologic 
exchange schedules. Traditional Dexter cultures 
utilizing these stromal cells are quite interest- 
ing, supporting erythroid and myeloid progeni- 
tor cell proliferation to a substantially greater 
extent than simple bone marrow adherent cell 
monolayers (Figure 1). Moreover, when incorpo- 
rated into a continuous perfusion bioreactor, 
these transfected stromal cells support continu- 
ous hematopoiesis, with continuous generation 
of HLA-DR' progenitor cells, for at least 100 
days. 
Based upon these results, experiments are 
now under way evaluating the effect of other 
candidate hematopoietic growth factors, includ- 
ing IL-6, IL-la and G-CSF. In addition, we are 
exploring the potential utility of alternative 
source of stromal cells for direct hematopoietic 
cultures. For example, based upon classic trans- 
plantation experiments, splenic fibroblasts might 
be a superior source of stromal cells to support 
erythropoiesis. We are therefore creating and 
testing the effects of distinct stromal cell types 
transfected with a variety of functional cDNAs. 
In addition, we are incorporating information 
from metabolic and molecular studies on iso- 
lated stromal cells into the design of specifically 
tailored hematopoietic bioreactors. 
PROSPECTS FOR HEMATOPOIETIC 
CULTURE BIOREACTORS 
Successful construction of hematopoietic 
bioreactors will have a tremendous impact on 
hematopoietic cell biology and on clinical prac- 
tice. First, it will permit the detailed study of 
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normal versus leukemic hematopoiesis in an in 
vitro system that accurately mimics the in vivo 
physiology. Second, it will permit the ex vivo 
manipulation of hematopoietic stem cells. This 
has major applications, including stem cell ex- 
pansion for allogeneic transplantation, stem cell 
purging for the selective removal of tumor cells 
prior to autologous reinfusion, and transduction 
of hematopoietic stem cells for gene therapy. 
Finally, such bioreactors would permit the pro- 
duction of mature blood cells, under controlled 
conditions, for transfusion therapy. With over 
30 million units of erythrocytes and over 10 
million units of platelets transfused annually, 
this represents a tremendous demand on the 
health care system, and a extraordinary opportu- 
nity for bioengineering to circumvent the infec- 
tious hazards of volunteer donors. 
In summary, successful ex vivo reconstruc- 
tion of functioning human bone marrow would 
be a fundamental achievement in bioengineer- 
ing and clinical research. The bone marrow is 
the source of pluripotent hematopoietic stem 
cells, the cells that give rise to all of the blood 
elements. Clinically, successful reconstruction 
of human bone marrow would permit the con- 
trolled production of mature blood cells for trans- 
fusion therapy, and immature bone marrow stem 
cells for bone marrow transplantation. With the 
recent advances in hematopoietic cell biology, 
molecular genetics, and cellular bioengineering, 
future research efforts should make significant 
strides towards to productively tackle and solve 
these problems. 
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